Evercore ISI downgraded BioCryst (BCRX) to In Line from Outperform with a price target of $8, down from $12. Though Orladeyo “should have some nice longevity,” the firm doesn’t see the product as “a winner in the HAE space,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX: